News & Events

selectION appoints Antonius Schuh as new CEO

News

Dr. Schuh has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences industries and has served as CEO of five life sciences companies, including Arcturus Bioscience, AviaraDx (now bioTheranostics), Sequenom (NASDAQ: SQNM), Sorrento Therapeutics (NASDAQ: SRNE) and Trovagene (NASDAQ: TROV). In each case he developed the company’s strategy based on a focused value proposition, oversaw the execution of such strategy, and secured funding to achieve transforming milestones, including multiple product launches. He delivered significant returns for investors at exit (public offering or acquisition).

He is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

Menu